Melanoma Vaccine Trial
6 articles from 4 countries
Moderna and Merck announced promising Phase 3 trial results for an experimental mRNA melanoma vaccine combined with Keytruda. The personalized therapy aims to prevent melanoma recurrence. The announcement caused Moderna's stock to surge.
Moderna shares surge after it says experimental mRNA cancer treatment passed key test
- Moderna announced initial results from a study of an experimental mRNA cancer treatment. - The treatment, developed with Merck, targets individual patients' tumor mutations and is paired with Merck's Keytruda immunotherapy drug. - Early data suggests the combination therapy helped melanoma patients live longer without cancer returning or spreading compared to Keytruda alone, causing Moderna's sh…
First mRNA cancer drug developed by Moderna and Merck shows promise in reducing melanoma recurrence
- Moderna and Merck have developed the first personalized mRNA cancer treatment drug, which has shown success in reducing melanoma recurrence in clinical trials. - Taiwanese hematology-oncology physic…
Moderna's Personalized Cancer Vaccine Succeeds in Phase 3 Trial; Domestic Tech Aims for 2027 Clinical Challenge | Dong-A Ilbo (KR) | Korean News | Health & Science | Positive | News | Unclear Sourcing | Announced
- Moderna's personalized mRNA cancer vaccine has shown positive results in a Phase 3 clinical trial for melanoma. - South Korean company Neogene Logic is preparing to apply for clinical trial approval…
Experimental melanoma vaccine shows promise, but data details awaited
- Pharmaceutical companies Moderna and Merck announced preliminary positive results for an experimental melanoma vaccine combined with Keytruda. - The trial involved 1,137 patients who had undergone s…
How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer
- Moderna announced a "landmark moment" for its experimental mRNA vaccine aimed at preventing melanoma recurrence. - The vaccine, used with Merck's Keytruda, is personalized based on a patient's tumor…
Moderna Cancer Vaccine Trial Success Fuels 177% Stock Surge
- Moderna announced its personalized mRNA cancer vaccine, developed with Merck, met its primary endpoint in a Phase 3 trial for high-risk melanoma patients. - The vaccine, known as intisemera autogene…
